TREATMENT OF VHL-NEGATIVE TUMORS

The present invention relates to methods of treating VHL-negative tumors (e.g., VHL-negative renal cell carcinomas, such as clear-cell renal cell carcinomas, VHL-negative kidney adenocarcinomas, VHL-negative hemangioblastomas of the central nervous system, VHL-negative pheochromocytomas, VHL-negative endolymphatic sac tumors of the inner ear, VHL-negative epididymal and broad ligament cystadenomas, and VHL-negative islet-cell tumors of the pancreas) in a subject in need of treatment comprising administering to the subject a therapeutically effective amount of a G-rich oligonucleotide (GRO).